Spatial Profiling of Ovarian Carcinoma and Tumor Microenvironment Evolution under Neoadjuvant Chemotherapy

Elisa Yaniz‐Galende, Qinghe Zeng, Juan Francisco Grau-Béjar, Christophe Klein, Félix Blanc‐Durand, Audrey Le Formal, Éric Pujade-Lauraine, Laure Chardin, Elodie Edmond, Virginie Marty, Isabelle Ray‐Coquard, Florence Joly, Gwénaël Ferron, Patricia Pautier, Dominique Berton-Rigaud, Alain Lortholary, Nadine Dohollou, Christophe Desauw, Michel Fabbro, Emmanuelle Malaurie, Nathalie Bonichon-Lamaichhane, Diana Bello Roufai, Justine Gantzer, Étienne Rouleau, Catherine Genestie, Alexandra LéaryClinical 2024 · DOI

Abstract

Several iTMEs exist during tumor evolution, and the NACT impact on iTME is heterogeneous. Clustering analysis of patients unravels several IC subsets within ovarian cancer and can guide future personalized approaches. Targeting different checkpoints such as TIM3, LAG3, and IDO1, more prevalent than PDL1, could more effectively harness antitumor immunity in this anti-PDL1-resistant malignancy.
BibTeX
@inproceedings{yanizgalende2024spatial,
  author = {Elisa Yaniz‐Galende and Qinghe Zeng and Juan Francisco Grau-Béjar and Christophe Klein and Félix Blanc‐Durand and Audrey Le Formal and Éric Pujade-Lauraine and Laure Chardin and Elodie Edmond and Virginie Marty and Isabelle Ray‐Coquard and Florence Joly and Gwénaël Ferron and Patricia Pautier and Dominique Berton-Rigaud and Alain Lortholary and Nadine Dohollou and Christophe Desauw and Michel Fabbro and Emmanuelle Malaurie and Nathalie Bonichon-Lamaichhane and Diana Bello Roufai and Justine Gantzer and Étienne Rouleau and Catherine Genestie and Alexandra Léary},
  title = {{Spatial Profiling of Ovarian Carcinoma and Tumor Microenvironment Evolution under Neoadjuvant Chemotherapy}},
  booktitle = {Clinical},
  year = {2024},
  doi = {10.1158/1078-0432.ccr-23-3836},
}

Loading related content...

Figure